New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For SNY;BMY;MRK;JNJ;NVS;ABT;CELG;PFE;SHPG;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 >>
January 25, 2016
10:57 EDTCELGCelgene management to meet with Evercore ISI
Meeting to be held in Canada on February 1 hosted by Evercore ISI.
10:55 EDTNVS, SNYRegeneron slips after analyst says sell to avoid risk from Amgen patent suit
Shares of Regeneron Pharmaceuticals (REGN) fell in morning trading after an analyst at Chardan downgraded the stock to Sell, citing risk from a patent lawsuit in which the biopharmaceutical company is involved. CHARDAN SAYS SELL: Chardan Capital Markets analyst Gbola Amusa downgraded Regeneron to Sell from Neutral this morning, while reducing his price target on shares to $400 from $525. In a note to clients, Amusa said he believes that Regeneron is likely to face significant risks from the upcoming patent infringement case for Praluent. The suit could be a key driver of the company's share price performance in the near future, the analyst said. Regeneron, along with its partner Sanofi (SNY), launched Praluent in the U.S. last year, after the October 2014 filing of a patent infringement suit by Amgen (AMGN) relating to patents for "monoclonal antibodies that bind PCSK9," Amusa noted. The analyst believes that since Regeneron and Sanofi "likely" infringe Amgen's patents for Repatha, the Regeneron-Sanofi partnership could seek to settle the ahead of the trial by agreeing to pay 10%-20% or more of royalties to Amgen for U.S. Praluent sales. Amusa said that "such an outcome we estimate could transfer roughly $750M of operating income per year to Amgen." Further, Amusa said that catalysts surrounding the patent infringement trial are "likely to play out from late February to late March," and concedes that "both sides have good reasons to settle this case for a reasonable royalty." INCREASING COMPETITION: Amusa also noted that he sees increasing competitive risks in 2016 to Regeneron's Eylea from Novartis (NVS) and its partner Ophthotech (OPHT), which continue to progress Fovista into Phase III trials in wet AMD. WHAT'S NOTABLE: Roth Capital upgraded Regeneron to Buy from Neutral on January 19, based on valuation, as the firm said shares do not reflect the value of the company's upcoming catalysts. The firm also raised its price target to $555 from $543. The same day, Credit Suisse initiated Regeneron with a Neutral rating and $552 target. PRICE TARGET: Regeneron slipped 1.4% to $476.02 in morning trading.
10:00 EDTBMYOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: American Eagle (AEO) downgraded to Hold from Buy at BB&T... American Express (AXP) downgraded on weak revenue outlook at Argus... Bristol-Myers (BMY) downgraded to Market Perform from Outperform at BMO Capital... Caterpillar (CAT) downgraded to Sell from Neutral at Goldman... Crestwood Equity (CEQP) downgraded to Neutral on potential distribution cut at Baird... Cummins (CMI) downgraded to Neutral from Buy at Citi... Federal Realty (FRT) downgraded to Hold from Buy at Evercore ISI... GKN PLC (GKNLY) downgraded to Neutral from Outperform at Credit Suisse... Galapagos NV (GLPG) downgraded to Neutral from Buy at GoldmanvHortonworks (HDP) downgraded to Perform from Outperform at Oppenheimer... International Flavors (IFF) downgraded on headwinds at Stifel... International Paper (IP) downgraded to Neutral from Buy at Citi... JPMorgan (JPM) downgraded to Neutral from Buy at Nomura... KapStone (KS) downgraded to Underperform from Neutral at Macquarie... Mosaic (MOS) downgraded to Neutral from Overweight at JPMorgan... NetSuite (N) downgraded to Equal Weight from Overweight at Stephens... ONEOK Partners (OKS) downgraded to Neutral at Baird... OvaScience (OVAS) downgraded to Perform from Outperform at Oppenheimer... Packaging Corp. (PKG) downgraded to Neutral from Buy at Citi... Potash (POT) downgraded to Neutral from Overweight at JPMorgan... Power Solutions (PSIX) downgraded to Neutral from Overweight at Piper Jaffray... Raymond James (RJF) downgraded to Neutral from Buy at Nomura... Regeneron (REGN) downgraded to Sell from Neutral at Chardan... SanDisk (SNDK) downgraded to Underperform from Outperform at CLSA... Toll Brothers (TOL) downgraded to Market Perform from Outperform at JMP Securities... Twitter (TWTR) downgraded to Hold from Buy at Stifel... WPX Energy (WPX) downgraded to Sector Perform from Outperform at Iberia... WestRock (WRK) downgraded to Neutral from Buy at BofA/Merrill... Whole Foods (WFM) downgraded to Underperform from Market Perform at BMO Capital... Zurich Insurance (ZURVY) downgraded to Neutral from Outperform at Exane BNP Paribas.
09:03 EDTMRKOn The Fly: Pre-market Movers
HIGHER: Tyco (TYC) and Johnson Controls (JCI), up 9% and 1%, respectively, after announcing a definitive merger agreement. Johnson Controls shareholders will own approximately 56% of the equity of the combined company, while current Tyco shareholders will own approximately 44%... SunEdison (SUNE), up 10% after the Wall Street Journal reported that the company is set to give David Einhorn's Greenlight Capital a seat on its board... Affimed Therapeutics (AFMD), up 26% after entering a clinical research collaboration in immuno-oncology with Merck (MRK). UP AFTER EARNINGS: McDonald's (MCD), up 3%... LOWER: Twitter (TWTR), down 5% after its CEO Jack Dorsey confirmed in a tweet last night that several executives are departing the company. Media reports also indicate that, as part of its shake-up, Twitter intends to bring in two new members to its board as soon as this week... OncoMed (OMED), down 38% after an independent data safety monitoring board remarked on several findings regarding futility of the company's Phase 2 ALPINE clinical trial... Medivation (MDVN), down 7% after FDA places investigational new drug application for MDV9300 on partial clinical hold... International Paper (IP), down 4.8%, Packaging Corp. (PKG), down 4.8%, WestRock (WRK), down 6%, after Pulp & Paper Week reduced January kraftliner and corrugated medium prices... Caterpillar (CAT), down 4% after Goldman cuts rating to sell... Regeneron (REGN), down 3% after downgraded at Chardan to sell. DOWN AFTER EARNINGS: Kimberly-Clark (KMB), down 2.5%.
08:27 EDTBMYBristol-Myers downgraded at BMO Capital
As noted earlier, BMO Capital downgraded Bristol-Myers to Market Perform from Outperform. The firm says that its positive thesis on clinical catalysts for the company's Opdivo drug has "mostly materialized." Target to $70 from $74.
08:04 EDTBMYAgilent's Dako announces FDA expanded approval of Dako PD-L1 IHC 28-8 pharmDx
Subscribe for More Information
07:02 EDTSHPGShire resubmits NDA for lifitegrast to FDA
Subscribe for More Information
06:53 EDTJNJ, GSKGlaxo, Astra, J&J partner with universities in drug research fund, Reuters says
Subscribe for More Information
06:05 EDTBMYBristol-Myers downgraded to Market Perform from Outperform at BMO Capital
Subscribe for More Information
05:36 EDTCELGStocks with implied volatility below IV index mean; CELG INTC
Subscribe for More Information
05:19 EDTMRKAffimed Therapeutics enters into collaboration with Merck
Subscribe for More Information
January 24, 2016
13:50 EDTBMYBristol-Myers says FDA expands indication for Opdivo-Yervoy
Bristol-Myers Squibb announced that the FDA has approved Opdivo, or nivolumab, in combination with Yervoy, or ipilimumab, for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma. "This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials," the company noted. The approval expands the original indication for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma to include patients, regardless of BRAF mutational status, based on data from the Phase 3 CheckMate -067 trial. The FDA also expanded the use of Opdivo as a single-agent to include previously untreated BRAF mutation-positive advanced melanoma patients.
January 22, 2016
15:35 EDTCELGCelgene presents analyses of Abraxane studies
Subscribe for More Information
15:22 EDTJNJJohnson & Johnson volatility elevated into Q4 and outlook
Subscribe for More Information
09:29 EDTBMYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: ABB (ABB) upgraded to Neutral from Sell at UBS... ACADIA (ACAD) upgraded to Overweight from Neutral at Piper Jaffray... ASML (ASML) upgraded to Hold from Sell at Deutsche Bank... Alaska Air (ALK) upgraded to Buy from Hold at Deutsche Bank... Arrow Electronics (ARW) upgraded to Buy from Neutral at Longbow... Avnet (AVT) upgraded to Buy from Neutral at Longbow... Avon Products (AVP) upgraded to Overweight from Neutral at Piper Jaffray... BankUnited (BKU) upgraded to Buy from Hold at Sandler O'Neill... Barclays (BCS) upgraded to Hold from Sell at Berenberg... Bristol-Myers (BMY) upgraded to Buy from Hold at Berenberg... CA Technologies (CA) upgraded to Buy from Neutral at Mizuho... CaixaBank (CAIXY) upgraded to Buy from Neutral at Nomura... Canadian Pacific (CP) upgraded to Outperform from Sector Perform at RBC Capital... Cardinal Financial (CFNL) upgraded to Outperform from Market Perform at Keefe Bruyette... Columbia Sportswear (COLM) upgraded to Outperform at Baird... Dr Pepper Snapple (DPS) upgraded to Outperform from Underperform at CLSA... Gorman-Rupp (GRC) upgraded to Outperform from Neutral at Boenning & Scattergood... Independent Bank (INDB) upgraded to Buy from Neutral at Compass Point... JD.com (JD) upgraded to Buy from Neutral at Nomura... KeyCorp (KEY) upgraded to Overweight from Equal Weight at Stephens... Lincoln National (LNC) upgraded to Strong Buy from Outperform at Raymond James... Masco (MAS) upgraded to Outperform at Baird... MetLife (MET) upgraded to Strong Buy from Market Perform at Raymond James... Northern Trust (NTRS) upgraded to Buy from Hold at Sandler O'Neill... Pacific Continental (PCBK) upgraded to Outperform at Keefe Bruyette... Qualcomm (QCOM) upgraded to Outperform from Market Perform at Northland... SL Green Realty (SLG) upgraded to Buy from Neutral at SunTrust... SVB Financial (SIVB) upgraded to Overweight from Neutral at Piper Jaffray... SunPower (SPWR) upgraded to Overweight from Equal Weight at Barclays... WEX Inc. (WEX) upgraded to Outperform from Market Perform at Wells Fargo.
09:20 EDTSHPGShire completes acquisition of Dyax for $5.9B
Subscribe for More Information
08:11 EDTBMY, MRKMerck price target lowered to $58 from $67 at Leerink
Leerink analyst Seamus Fernandez lowered his price target for Merck (MRK) to $58 citing his expectation for Bristol-Myers (BMY) to remain the leader in the immuno-oncology market as well as a "harder to penetrate" hepatitis C virus market. Nonetheless, the analyst believes headwinds facing Januvia, Keytruda and the HCV franchise are reflected in Merck shares at current levels. Fernandez keeps a Market Perform rating on the name.
07:31 EDTCELGCelgene says 10 ABRAXANE studies presented at 2016 ASCO GI
Celgene announced that 10 studies highlighting combinations that include a foundation of ABRAXANE and gemcitabine are being presented during the 2016 ASCO Gastrointestinal Cancers Symposium, establishing the therapy as the foundation for research in first-line metastatic pancreatic cancer. "ABRAXANE is the only chemotherapy approved in combination with gemcitabine based on an improvement in overall survival for first line metastatic pancreatic cancer patients and is fast becoming the standard of care in this extremely difficult to treat disease," said Jacqualyn A. Fouse, Ph.D., President, Hematology/Oncology for Celgene. "We are excited that ABRAXANE plus gemcitabine is serving as the foundation for a new wave of potential treatments that may further improve the treatment paradigm in this disease and are fully committed to continuing to serve these patients."
06:31 EDTBMYLeerink recommends buying Bristol-Myers shares now
Leerink analyst Seamus Fernandez recommends buying shares of Bristol-Myers now saying the company's dominance of the immuno-oncology market "is likely to continue for at least the next several years." The analyst expects Bristol to see "substantial operating leverage" in the second half of 2016 as the company annualizes the loss of Abilify profits. He raised his price target for the shares to $78 from $77 and keeps an Outperform rating on the name.
06:07 EDTBMYBristol-Myers upgraded to Buy from Hold at Berenberg
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use